Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 16, 2023

BUY
$0.39 - $0.71 $5,460 - $9,940
14,000 New
14,000 $5,000
Q4 2021

Feb 14, 2022

SELL
$2.05 - $3.2 $81,590 - $127,360
-39,800 Reduced 64.93%
21,500 $44,000
Q3 2021

Nov 15, 2021

SELL
$2.54 - $4.07 $62,230 - $99,715
-24,500 Reduced 28.55%
61,300 $189,000
Q2 2021

Aug 11, 2021

SELL
$2.57 - $4.85 $23,130 - $43,650
-9,000 Reduced 9.49%
85,800 $349,000
Q1 2021

May 17, 2021

SELL
$1.9 - $2.82 $3,800 - $5,640
-2,000 Reduced 2.07%
94,800 $234,000
Q4 2020

Feb 16, 2021

SELL
$1.15 - $2.4 $77,050 - $160,800
-67,000 Reduced 40.9%
96,800 $206,000
Q3 2020

Nov 16, 2020

BUY
$1.11 - $1.68 $113,664 - $172,032
102,400 Added 166.78%
163,800 $198,000
Q2 2020

Aug 14, 2020

SELL
$1.69 - $4.2 $27,378 - $68,040
-16,200 Reduced 20.88%
61,400 $106,000
Q1 2020

May 15, 2020

SELL
$1.26 - $3.38 $177,408 - $475,904
-140,800 Reduced 64.47%
77,600 $205,000
Q4 2019

Feb 14, 2020

SELL
$0.86 - $1.44 $11,266 - $18,864
-13,100 Reduced 5.66%
218,400 $293,000
Q3 2019

Nov 14, 2019

BUY
$1.21 - $1.59 $242,726 - $318,954
200,600 Added 649.19%
231,500 $280,000
Q2 2019

Aug 14, 2019

SELL
$1.25 - $3.14 $2,000 - $5,024
-1,600 Reduced 4.92%
30,900 $47,000
Q1 2019

May 15, 2019

SELL
$2.79 - $4.09 $10,602 - $15,542
-3,800 Reduced 10.47%
32,500 $96,000
Q4 2018

Feb 14, 2019

SELL
$3.23 - $7.01 $209,950 - $455,650
-65,000 Reduced 64.17%
36,300 $122,000
Q3 2018

Nov 14, 2018

BUY
$6.86 - $9.97 $166,012 - $241,274
24,200 Added 31.39%
101,300 $734,000
Q2 2018

Aug 14, 2018

BUY
$2.88 - $8.67 $160,704 - $483,786
55,800 Added 261.97%
77,100 $530,000
Q1 2018

May 15, 2018

BUY
$2.92 - $3.81 $18,396 - $24,003
6,300 Added 42.0%
21,300 $63,000
Q4 2017

Feb 14, 2018

BUY
$2.99 - $4.85 $44,850 - $72,750
15,000
15,000 $46,000

Others Institutions Holding VSTM

About Verastem, Inc.


  • Ticker VSTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 210,000,000
  • Market Cap $1.09B
  • Description
  • Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...
More about VSTM
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.